![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: HLA-DPA1 |
Gene summary for HLA-DPA1 |
![]() |
Gene information | Species | Human | Gene symbol | HLA-DPA1 | Gene ID | 3113 |
Gene name | major histocompatibility complex, class II, DP alpha 1 | |
Gene Alias | DP(W3) | |
Cytomap | 6p21.32 | |
Gene Type | protein-coding | GO ID | GO:0001775 | UniProtAcc | P20036 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
3113 | HLA-DPA1 | GSM4909287 | Human | Breast | IDC | 6.52e-27 | 7.47e-01 | 0.2057 |
3113 | HLA-DPA1 | GSM4909290 | Human | Breast | IDC | 1.56e-05 | 2.71e-01 | 0.2096 |
3113 | HLA-DPA1 | GSM4909293 | Human | Breast | IDC | 9.07e-08 | 2.27e-01 | 0.1581 |
3113 | HLA-DPA1 | GSM4909305 | Human | Breast | IDC | 2.63e-02 | 2.19e-01 | 0.0436 |
3113 | HLA-DPA1 | GSM4909317 | Human | Breast | IDC | 8.08e-06 | 2.80e-01 | 0.1355 |
3113 | HLA-DPA1 | M1 | Human | Breast | IDC | 1.37e-17 | 5.64e-01 | 0.1577 |
3113 | HLA-DPA1 | M2 | Human | Breast | IDC | 1.83e-05 | 6.44e-01 | 0.21 |
3113 | HLA-DPA1 | NCCBC11 | Human | Breast | DCIS | 3.90e-09 | 8.54e-01 | 0.1232 |
3113 | HLA-DPA1 | NCCBC14 | Human | Breast | DCIS | 2.42e-07 | 4.77e-01 | 0.2021 |
3113 | HLA-DPA1 | NCCBC3 | Human | Breast | DCIS | 1.57e-73 | 1.47e+00 | 0.1198 |
3113 | HLA-DPA1 | NCCBC5 | Human | Breast | DCIS | 5.80e-28 | 9.67e-01 | 0.2046 |
3113 | HLA-DPA1 | P2 | Human | Breast | IDC | 4.77e-26 | 9.60e-01 | 0.21 |
3113 | HLA-DPA1 | DCIS2 | Human | Breast | DCIS | 1.03e-02 | 4.32e-02 | 0.0085 |
3113 | HLA-DPA1 | CA_HPV_1 | Human | Cervix | CC | 5.76e-10 | 6.60e-01 | 0.0264 |
3113 | HLA-DPA1 | CA_HPV_3 | Human | Cervix | CC | 4.76e-02 | -4.65e-01 | 0.0414 |
3113 | HLA-DPA1 | N_HPV_1 | Human | Cervix | N_HPV | 3.00e-05 | 2.45e-01 | 0.0079 |
3113 | HLA-DPA1 | CCI_1 | Human | Cervix | CC | 6.16e-10 | -1.04e+00 | 0.528 |
3113 | HLA-DPA1 | CCI_3 | Human | Cervix | CC | 9.65e-08 | -9.64e-01 | 0.516 |
3113 | HLA-DPA1 | CCII_1 | Human | Cervix | CC | 1.70e-18 | -1.04e+00 | 0.3249 |
3113 | HLA-DPA1 | Tumor | Human | Cervix | CC | 1.26e-17 | -5.58e-01 | 0.1241 |
Page: 1 2 3 4 5 6 7 8 9 10 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004212910 | Oral cavity | EOLP | regulation of T cell proliferation | 36/2218 | 171/18723 | 4.01e-04 | 3.58e-03 | 36 |
GO:000250115 | Oral cavity | EOLP | peptide antigen assembly with MHC protein complex | 8/2218 | 18/18723 | 5.58e-04 | 4.74e-03 | 8 |
GO:007066513 | Oral cavity | EOLP | positive regulation of leukocyte proliferation | 31/2218 | 150/18723 | 1.34e-03 | 9.33e-03 | 31 |
GO:000239910 | Oral cavity | EOLP | MHC class II protein complex assembly | 7/2218 | 16/18723 | 1.40e-03 | 9.58e-03 | 7 |
GO:000250310 | Oral cavity | EOLP | peptide antigen assembly with MHC class II protein complex | 7/2218 | 16/18723 | 1.40e-03 | 9.58e-03 | 7 |
GO:00024433 | Oral cavity | EOLP | leukocyte mediated immunity | 73/2218 | 440/18723 | 1.78e-03 | 1.16e-02 | 73 |
GO:000238112 | Oral cavity | EOLP | immunoglobulin production involved in immunoglobulin-mediated immune response | 17/2218 | 70/18723 | 2.78e-03 | 1.66e-02 | 17 |
GO:00506714 | Oral cavity | EOLP | positive regulation of lymphocyte proliferation | 27/2218 | 137/18723 | 5.24e-03 | 2.75e-02 | 27 |
GO:00329464 | Oral cavity | EOLP | positive regulation of mononuclear cell proliferation | 27/2218 | 138/18723 | 5.80e-03 | 2.94e-02 | 27 |
GO:00024604 | Oral cavity | EOLP | adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains | 58/2218 | 356/18723 | 7.27e-03 | 3.52e-02 | 58 |
GO:004578518 | Prostate | BPH | positive regulation of cell adhesion | 120/3107 | 437/18723 | 5.22e-09 | 1.90e-07 | 120 |
GO:002240716 | Prostate | BPH | regulation of cell-cell adhesion | 109/3107 | 448/18723 | 1.43e-05 | 1.85e-04 | 109 |
GO:001988218 | Prostate | BPH | antigen processing and presentation | 33/3107 | 106/18723 | 1.55e-04 | 1.36e-03 | 33 |
GO:004211010 | Prostate | BPH | T cell activation | 111/3107 | 487/18723 | 2.11e-04 | 1.72e-03 | 111 |
GO:004800217 | Prostate | BPH | antigen processing and presentation of peptide antigen | 22/3107 | 62/18723 | 2.45e-04 | 1.94e-03 | 22 |
GO:00018199 | Prostate | BPH | positive regulation of cytokine production | 105/3107 | 467/18723 | 5.18e-04 | 3.66e-03 | 105 |
GO:000715910 | Prostate | BPH | leukocyte cell-cell adhesion | 86/3107 | 371/18723 | 5.95e-04 | 4.11e-03 | 86 |
GO:001988417 | Prostate | BPH | antigen processing and presentation of exogenous antigen | 17/3107 | 47/18723 | 9.41e-04 | 5.94e-03 | 17 |
GO:190303710 | Prostate | BPH | regulation of leukocyte cell-cell adhesion | 78/3107 | 336/18723 | 9.95e-04 | 6.25e-03 | 78 |
GO:005086310 | Prostate | BPH | regulation of T cell activation | 76/3107 | 329/18723 | 1.32e-03 | 7.95e-03 | 76 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0516922 | Breast | IDC | Epstein-Barr virus infection | 45/867 | 202/8465 | 3.16e-07 | 6.05e-06 | 4.52e-06 | 45 |
hsa0461223 | Breast | IDC | Antigen processing and presentation | 24/867 | 78/8465 | 4.61e-07 | 8.33e-06 | 6.23e-06 | 24 |
hsa0414522 | Breast | IDC | Phagosome | 34/867 | 152/8465 | 8.00e-06 | 9.99e-05 | 7.48e-05 | 34 |
hsa0541623 | Breast | IDC | Viral myocarditis | 18/867 | 60/8465 | 1.85e-05 | 2.01e-04 | 1.50e-04 | 18 |
hsa0516624 | Breast | IDC | Human T-cell leukemia virus 1 infection | 40/867 | 222/8465 | 2.52e-04 | 2.21e-03 | 1.66e-03 | 40 |
hsa0532321 | Breast | IDC | Rheumatoid arthritis | 21/867 | 93/8465 | 3.69e-04 | 3.15e-03 | 2.36e-03 | 21 |
hsa0494014 | Breast | IDC | Type I diabetes mellitus | 12/867 | 43/8465 | 9.40e-04 | 7.28e-03 | 5.44e-03 | 12 |
hsa0533012 | Breast | IDC | Allograft rejection | 11/867 | 38/8465 | 1.09e-03 | 8.26e-03 | 6.18e-03 | 11 |
hsa0533210 | Breast | IDC | Graft-versus-host disease | 11/867 | 42/8465 | 2.66e-03 | 1.80e-02 | 1.35e-02 | 11 |
hsa0514012 | Breast | IDC | Leishmaniasis | 16/867 | 77/8465 | 4.35e-03 | 2.57e-02 | 1.92e-02 | 16 |
hsa0532010 | Breast | IDC | Autoimmune thyroid disease | 12/867 | 53/8465 | 6.29e-03 | 3.30e-02 | 2.47e-02 | 12 |
hsa0516932 | Breast | IDC | Epstein-Barr virus infection | 45/867 | 202/8465 | 3.16e-07 | 6.05e-06 | 4.52e-06 | 45 |
hsa0461233 | Breast | IDC | Antigen processing and presentation | 24/867 | 78/8465 | 4.61e-07 | 8.33e-06 | 6.23e-06 | 24 |
hsa0414532 | Breast | IDC | Phagosome | 34/867 | 152/8465 | 8.00e-06 | 9.99e-05 | 7.48e-05 | 34 |
hsa0541633 | Breast | IDC | Viral myocarditis | 18/867 | 60/8465 | 1.85e-05 | 2.01e-04 | 1.50e-04 | 18 |
hsa0516634 | Breast | IDC | Human T-cell leukemia virus 1 infection | 40/867 | 222/8465 | 2.52e-04 | 2.21e-03 | 1.66e-03 | 40 |
hsa0532331 | Breast | IDC | Rheumatoid arthritis | 21/867 | 93/8465 | 3.69e-04 | 3.15e-03 | 2.36e-03 | 21 |
hsa0494015 | Breast | IDC | Type I diabetes mellitus | 12/867 | 43/8465 | 9.40e-04 | 7.28e-03 | 5.44e-03 | 12 |
hsa0533013 | Breast | IDC | Allograft rejection | 11/867 | 38/8465 | 1.09e-03 | 8.26e-03 | 6.18e-03 | 11 |
hsa0533211 | Breast | IDC | Graft-versus-host disease | 11/867 | 42/8465 | 2.66e-03 | 1.80e-02 | 1.35e-02 | 11 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
HLA-DPA1 | CD4 | HLA-DPA1_CD4 | MHC-II | Breast | DCIS |
HLA-DPA1 | CD4 | HLA-DPA1_CD4 | MHC-II | Breast | Healthy |
HLA-DPA1 | CD4 | HLA-DPA1_CD4 | MHC-II | Breast | IDC |
HLA-DPA1 | CD4 | HLA-DPA1_CD4 | MHC-II | Cervix | ADJ |
HLA-DPA1 | CD4 | HLA-DPA1_CD4 | MHC-II | Cervix | CC |
HLA-DPA1 | CD4 | HLA-DPA1_CD4 | MHC-II | Cervix | Healthy |
HLA-DPA1 | CD4 | HLA-DPA1_CD4 | MHC-II | Cervix | Precancer |
HLA-DPA1 | CD4 | HLA-DPA1_CD4 | MHC-II | CRC | AD |
HLA-DPA1 | CD4 | HLA-DPA1_CD4 | MHC-II | CRC | ADJ |
HLA-DPA1 | CD4 | HLA-DPA1_CD4 | MHC-II | CRC | MSI-H |
HLA-DPA1 | CD4 | HLA-DPA1_CD4 | MHC-II | CRC | MSS |
HLA-DPA1 | CD4 | HLA-DPA1_CD4 | MHC-II | CRC | SER |
HLA-DPA1 | CD4 | HLA-DPA1_CD4 | MHC-II | Endometrium | ADJ |
HLA-DPA1 | CD4 | HLA-DPA1_CD4 | MHC-II | Endometrium | AEH |
HLA-DPA1 | CD4 | HLA-DPA1_CD4 | MHC-II | Endometrium | EEC |
HLA-DPA1 | CD4 | HLA-DPA1_CD4 | MHC-II | Endometrium | Healthy |
HLA-DPA1 | CD4 | HLA-DPA1_CD4 | MHC-II | HNSCC | ADJ |
HLA-DPA1 | CD4 | HLA-DPA1_CD4 | MHC-II | HNSCC | Healthy |
HLA-DPA1 | CD4 | HLA-DPA1_CD4 | MHC-II | HNSCC | OSCC |
HLA-DPA1 | CD4 | HLA-DPA1_CD4 | MHC-II | HNSCC | Precancer |
Page: 1 2 3 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
HLA-DPA1 | SNV | Missense_Mutation | c.397C>T | p.Pro133Ser | p.P133S | P20036 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-A2-A0CT-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | SD | |
HLA-DPA1 | SNV | Missense_Mutation | novel | c.325N>G | p.Asn109Asp | p.N109D | P20036 | protein_coding | deleterious(0.01) | probably_damaging(0.989) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
HLA-DPA1 | SNV | Missense_Mutation | rs770307009 | c.746N>A | p.Arg249His | p.R249H | P20036 | protein_coding | tolerated(0.21) | benign(0.005) | TCGA-CM-4747-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | fluorouracil | SD |
HLA-DPA1 | SNV | Missense_Mutation | rs371532700 | c.137C>T | p.Thr46Met | p.T46M | P20036 | protein_coding | deleterious(0.04) | possibly_damaging(0.895) | TCGA-G4-6295-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
HLA-DPA1 | SNV | Missense_Mutation | c.100N>A | p.Ala34Thr | p.A34T | P20036 | protein_coding | deleterious(0.03) | benign(0.106) | TCGA-G4-6304-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Chemotherapy | fluorouracil | PD | |
HLA-DPA1 | SNV | Missense_Mutation | c.484G>T | p.Gly162Cys | p.G162C | P20036 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-G4-6628-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
HLA-DPA1 | SNV | Missense_Mutation | rs751649425 | c.724N>A | p.Val242Ile | p.V242I | P20036 | protein_coding | tolerated(1) | benign(0) | TCGA-WS-AB45-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
HLA-DPA1 | SNV | Missense_Mutation | novel | c.446N>G | p.Asn149Ser | p.N149S | P20036 | protein_coding | tolerated(0.18) | benign(0.033) | TCGA-AP-A056-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
HLA-DPA1 | SNV | Missense_Mutation | rs761093053 | c.5N>A | p.Arg2His | p.R2H | P20036 | protein_coding | tolerated_low_confidence(0.56) | benign(0) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
HLA-DPA1 | SNV | Missense_Mutation | novel | c.718G>A | p.Gly240Ser | p.G240S | P20036 | protein_coding | deleterious(0.01) | probably_damaging(1) | TCGA-B5-A3FA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
3113 | HLA-DPA1 | CLINICALLY ACTIONABLE, DRUGGABLE GENOME, CELL SURFACE | peginterferon alfa-2b | 26387494 |
Page: 1 |